WRIB 2023 Poster: Bimiralizib distribution in human skin biopsies after topical administration obtained by validated quantitative mass spectrometry imaging
Quantitative MALDI Mass Spectrometry Imaging (QSMI) can be used to determine drug distribution in first-in-human studies
At WRIB 2023, Shane Karnik, Senior Laboratory Director at Aliri, presented a poster about utilizing QSMI to determine Bimiralizib distribution in human skin biopsies.
Recent clinical trial results validate Bimiralizib distribution in human skin and showcase:
- Robustness of MALDI MSI method
- Approach not limited to dermatology; already applied in oncology
- Absolute quantification allowed to determine if the compound reached the site of action
- Method allows to characterize small compound PK in clinical trial
- Method allows the characterization of the target engagement
Download our poster about utilizing QSMI to determine drug distribution.
